MicroRNAs in Alzheimer’s Disease: Function and Potential Applications as Diagnostic Biomarkers

Wei, Wei; Wang, Zhiyong; Ma, Lina; Zhang, Tingting; Cao, Yu; Li, Hao

doi:10.3389/fnmol.2020.00160

Cited by 69 publications

(63 citation statements)

References 188 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 4 Recently, aberrant changes in miRNAs have been discovered to participate in AD progression, and are considered candidate blood-based biomarkers of AD, as they have been found to guide the clinical diagnosis of AD. 5 , 6 Wang et al 7 reported that the expression levels of miR-433 were reduced in AD patients and that this miRNA has the potential to be a therapeutic target through improving Aβ-induced neurotoxicity. Yang et al 8 provided evidence for miR-133b to serve as a diagnostic biomarker of AD and revealed its neuroprotective role, which is exerted through maintenance of neuronal viability.…”

Section: Introductionmentioning

confidence: 99%

Serum miR-128 Serves as a Potential Diagnostic Biomarker for Alzheimer’s Disease

Zhang¹,

Han²,

Xu³

et al. 2021

NDT

View full text Add to dashboard Cite

Background Although numerous microRNAs (miRNAs) have been discovered to participate in the progression of Alzheimer’s disease (AD), they are still difficult to apply in clinical work. Thus, the identification of novel miRNAs and clarification of their clinical significance are importing for improving the diagnosis and treatment of AD. The purpose of this study was to analyze the expression of miR-128 and its diagnostic value in patients with AD. Patients and Methods In this study, 117 AD patients and 106 controls were enrolled, and the demographic data, biochemical parameters and serum miR-128 levels were collected. These data were then used to build a logistic regression model, and receiver operating characteristic (ROC) curves were drawn to evaluate the diagnostic value of miR-128. The relationships between miR-128 and inflammatory factors (IL-1β/TNF-α) were also analyzed from clinical serum data. Results Our study found that miR-128 was significantly upregulated in the serum samples of AD patients compared with controls, and that this upregulation was negatively correlated with Mini-Mental State Examination (MMSE) scores ( r = −0.687, P < 0.01). ROC curve showed that the area under the curve of miR-128 was 0.831. Logistic regression analyses showed that glycosylated hemoglobin (HbA1c) levels, low-density lipoprotein (LDL) levels, MMSE scores and serum miR-128 levels were statistically significant ( P < 0.01), and the ROC curve of the combined detection of these variables was 0.906. The serum miR-128 levels in AD patients were positively correlated with the serum IL-1β ( r =0.798, P <0.01) and serum TNF-α levels ( r =0.733, P <0.01). Conclusion Serum miR-128 is a candidate diagnostic biomarker in AD patients who achieved good diagnostic performance when used alone or in combination with other factors and may have the potential to be a novel therapeutic target for neuroinflammation.

show abstract

Section: Introductionmentioning

confidence: 99%

Serum miR-128 Serves as a Potential Diagnostic Biomarker for Alzheimer’s Disease

Zhang¹,

Han²,

Xu³

et al. 2021

NDT

View full text Add to dashboard Cite

show abstract

“…Another area of interest are miRNAs that regulate MAPT affecting tau accumulation and relevant protein kinases affecting tau phosphorylation [ 68 , 69 ], looking at both of the distinct neuropathologies associated with AD. In-depth reviews of other miRNAs currently associated with AD have been expanded on elsewhere [ 61 , 70 , 71 ], however, further studies will be required to assess if a panel of miRNA biomarkers is sufficient to be clinically and diagnostically useful in the identification of AD patients, discerning AD patients from other neurodegenerative disease, or to monitor the progression of AD.…”

Section: Alzheimer’s Diseasementioning

confidence: 99%

Genetic and Transcriptomic Biomarkers in Neurodegenerative Diseases: Current Situation and the Road Ahead

Lake

Storm

Makarious

et al. 2021

Cells

View full text Add to dashboard Cite

Neurodegenerative diseases are etiologically and clinically heterogeneous conditions, often reflecting a spectrum of disease rather than well-defined disorders. The underlying molecular complexity of these diseases has made the discovery and validation of useful biomarkers challenging. The search of characteristic genetic and transcriptomic indicators for preclinical disease diagnosis, prognosis, or subtyping is an area of ongoing effort and interest. The next generation of biomarker studies holds promise by implementing meaningful longitudinal and multi-modal approaches in large scale biobank and healthcare system scale datasets. This work will only be possible in an open science framework. This review summarizes the current state of genetic and transcriptomic biomarkers in Parkinson’s disease, Alzheimer’s disease, and amyotrophic lateral sclerosis, providing a comprehensive landscape of recent literature and future directions.

show abstract

“…It exceeds the purpose of this paper to describe the functions and potential applications of the numerous miRNAs in terms of diagnostic biomarkers since comprehensive reviews have been already written for AD [ 26 , 27 , 28 ] and PD [ 29 , 30 , 31 ], amyotrophic lateral sclerosis (ALS) [ 29 , 30 , 31 , 32 ], multiple sclerosis (MS) [ 33 , 34 ], traumatic brain injury (TBI) [ 35 , 36 ], or development-related syndromes, such as autism spectrum disorder (ASD) [ 37 , 38 ]. Instead, both in the central nervous system (CNS) and in the cerebral spinal fluid (CSF), miRNAs recruitment has boosted a novel impulse for the prognosis but, more strikingly, for neural regenerative medicine, shedding light on feasible translational brain applications that fill the present gap of clinical interventions represented by NSC transplantation.…”

Section: Mirnas Bridging Stemness and Cell Death In Neurogenesismentioning

confidence: 99%

MicroRNAs at the Crossroad of the Dichotomic Pathway Cell Death vs. Stemness in Neural Somatic and Cancer Stem Cells: Implications and Therapeutic Strategies

Diana

Gaido²,

Maxia

et al. 2020

IJMS

View full text Add to dashboard Cite

Stemness and apoptosis may highlight the dichotomy between regeneration and demise in the complex pathway proceeding from ontogenesis to the end of life. In the last few years, the concept has emerged that the same microRNAs (miRNAs) can be concurrently implicated in both apoptosis-related mechanisms and cell differentiation. Whether the differentiation process gives rise to the architecture of brain areas, any long-lasting perturbation of miRNA expression can be related to the occurrence of neurodevelopmental/neuropathological conditions. Moreover, as a consequence of neural stem cell (NSC) transformation to cancer stem cells (CSCs), the fine modulation of distinct miRNAs becomes necessary. This event implies controlling the expression of pro/anti-apoptotic target genes, which is crucial for the management of neural/neural crest-derived CSCs in brain tumors, neuroblastoma, and melanoma. From a translational point of view, the current progress on the emerging miRNA-based neuropathology therapeutic applications and antitumor strategies will be disclosed and their advantages and shortcomings discussed.

show abstract

MicroRNAs in Alzheimer’s Disease: Function and Potential Applications as Diagnostic Biomarkers

Cited by 69 publications

References 188 publications

Serum miR-128 Serves as a Potential Diagnostic Biomarker for Alzheimer’s Disease

Serum miR-128 Serves as a Potential Diagnostic Biomarker for Alzheimer’s Disease

Genetic and Transcriptomic Biomarkers in Neurodegenerative Diseases: Current Situation and the Road Ahead

MicroRNAs at the Crossroad of the Dichotomic Pathway Cell Death vs. Stemness in Neural Somatic and Cancer Stem Cells: Implications and Therapeutic Strategies

Contact Info

Product

Resources

About